Host-directed therapies offer novel opportunities for the fight against tuberculosis

Drug Discovery Today

Volumn 22, Issue 8, 2017, Pages 1250-1257

  Machelart, Arnaud ^a   Song, Ok Ryul ^a   Hoffmann, Eik ^a   Brodin, Priscille ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; LIPID; NEW DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE R; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; AUTOPHAGY; BACTERIAL IMMUNITY; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM IDENTIFICATION; CELL MATURATION; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG TARGETING; DRUG THERAPY; GRANULOMA; HIGH THROUGHPUT SCREENING; HOST CELL; HOST DIRECTED THERAPY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOMODULATION; INTRACELLULAR SPACE; LIPID METABOLISM; LUNG FUNCTION; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NECROSIS; NONHUMAN; PATHOGENESIS; PHAGOSOME; REVIEW; TUBERCULOSIS; ANIMAL; DRUG EFFECT; IMMUNOLOGY; LUNG; MICROBIOLOGY;

ANIMALS; ANTITUBERCULAR AGENTS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LUNG; MACROPHAGES; TUBERCULOSIS;

EID: 85020021671     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2017.05.005     Document Type: Review

References (66)

1. WHO, Global Tuberculosis Report., 2016, WHO.
2. Dheda, K., et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet. Respir. Med., 2017, 10.1016/S2213-2600(17)30079-6 Published online March 15, 2017.
3. Torrelles, J.B., Schlesinger, L.S., Integrating lung physiology, immunology, and tuberculosis. Trends Microbiol., 2017, 10.1016/j.tim.2017.03.007 Published online March 30, 2017.
4. Cambier, C.J., et al. Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell 159 (2014), 1497–1509.
5. Philips, J.A., Ernst, J.D., Tuberculosis pathogenesis and immunity. Annu. Rev. Pathol. 7 (2012), 353–384.
6. Augenstreich, J., et al. ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. Cell Microbiol., 2017, 10.1111/cmi.12726 Published online January 17, 2017.
7. Simeone, R., et al. Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. PLoS Pathog., 11, 2015, e1004650.
8. Watson, R.O., et al. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 150 (2012), 803–815.
9. Jung, Y.J., et al. Evidence inconsistent with a negative influence of T helper 2 cells on protection afforded by a dominant T helper 1 response against Mycobacterium tuberculosis lung infection in mice. Infect. Immun. 70 (2002), 6436–6443.
10. Davis, J.M., Ramakrishnan, L., The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136 (2009), 37–49.
11. Martin, C.J., et al. A bug's life in the granuloma. Semin. Immunopathol. 38 (2016), 213–220.
12. Taylor, J.L., et al. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect. Immun. 74 (2006), 6135–6144.
13. Chao, M.C., Rubin, E.J., Letting sleeping dos lie: does dormancy play a role in tuberculosis?. Annu. Rev. Microbiol. 64 (2010), 293–311.
14. Marakalala, M.J., et al. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat. Med. 22 (2016), 531–538.
15. Prideaux, B., et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat. Med. 21 (2015), 1223–1227.
16. Liu, Y., et al. Immune activation of the host cell induces drug tolerance in Mycobacterium tuberculosis both in vitro and in vivo. J. Exp. Med. 213 (2016), 809–825.
17. Martin, C.J., et al. Efferocytosis is an innate antibacterial mechanism. Cell Host Microbe 12 (2012), 289–300.
18. Napier, R.J., et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 10 (2011), 475–485.
19. Rohde, K., et al. Mycobacterium tuberculosis and the environment within the phagosome. Immunol. Rev. 219 (2007), 37–54.
20. Brodin, P., et al. High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. PLoS Pathog., 6, 2010, e1001100.
21. Fratti, R.A., et al. Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J Cell Biol. 154 (2001), 631–644.
22. Fratti, R.A., et al. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 5437–5442.
23. Bruns, H., et al. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J. Immunol. 189 (2012), 4069–4078.
24. Anand, S.P., Selvaraj, P., Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis. Clin. Immunol. 133 (2009), 126–131.
25. Liu, P.T., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 (2006), 1770–1773.
26. Martineau, A.R., et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 19013–19017.
27. Nursyam, E.W., et al. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med. Indones. 38 (2006), 3–5.
28. Wejse, C., et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 179 (2009), 843–850.
29. Russell, D.G., et al. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat. Immunol. 10 (2009), 943–948.
30. Singh, V., et al. Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype. Cell Host Microbe 12 (2012), 669–681.
31. Kiss, M., et al. The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: from physiology to pathology. J. Allergy Clin. Immunol. 132 (2013), 264–286.
32. Mahajan, S., et al. Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARgamma and TR4 for survival. J. Immunol. 188 (2012), 5593–5603.
33. Rajaram, M.V., et al. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking mannose receptor recognition to regulation of immune responses. J. Immunol. 185 (2010), 929–942.
34. Xu, Y., et al. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27 (2007), 135–144.
35. Kuijl, C., et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 450 (2007), 725–730.
36. Gupta, A., et al. Targeted pulmonary delivery of inducers of host macrophage autophagy as a potential host-directed chemotherapy of tuberculosis. Adv. Drug Deliv. Rev. 102 (2016), 10–20.
37. Kim, J.J., et al. Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. Cell Host Microbe 11 (2012), 457–468.
38. Behar, S.M., et al. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy?. Nat. Rev. Microbiol. 8 (2010), 668–674.
39. Roca, F.J., Ramakrishnan, L., TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 153 (2013), 521–534.
40. Restrepo, B.I., Metformin: candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients. Tuberculosis (Edinb) 101S (2016), S69–S72.
41. Singhal, A., et al. Metformin as adjunct antituberculosis therapy. Sci. Transl. Med., 6, 2014, 263ra159.
42. Tobin, D.M., et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 140 (2010), 717–730.
43. Ehrt, S., et al. Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J. Exp. Med. 194 (2001), 1123–1140.
44. Dawson, R., et al. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One, 4, 2009, e6984.
45. Milanes-Virelles, M.T., et al. Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study. BMC Infect. Dis., 8, 2008, 17.
46. Wu, K., et al. Improved control of tuberculosis and activation of macrophages in mice lacking protein kinase R. PLoS One, 7, 2012, e30512.
47. Friedland, J.S., et al. Differential regulation of MMP-1/9 and TIMP-1 secretion in human monocytic cells in response to Mycobacterium tuberculosis. Matrix Biol. 21 (2002), 103–110.
48. Volkman, H.E., et al. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327 (2010), 466–469.
49. Datta, M., et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 1827–1832.
50. Lam, K.K., et al. Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS Pathog., 8, 2012, e1002691.
51. Fukutomi, Y., et al. Apoptosis-inducing activity of clofazimine in macrophages. Antimicrob. Agents Chemother. 55 (2011), 4000–4005.
52. Walker, N.F., et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 185 (2012), 989–997.
53. Andries, K., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307 (2005), 223–227.
54. Matsumoto, M., et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med., 3, 2006, e466.
55. Christophe, T., et al. High content screening identifies decaprenyl-phosphoribose 2’ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog., 5, 2009, e1000645.
56. Queval, C.J., et al. A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. J. Vis. Exp., 83, 2014, e51114.
57. Sorrentino, F., et al. Development of an intracellular screen for new compounds able to inhibit Mycobacterium tuberculosis growth in human macrophages. Antimicrob. Agents Chemother. 60 (2015), 640–645.
58. Stanley, S.A., et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog., 10, 2014, e1003946.
59. Sundaramurthy, V., et al. Integration of chemical and RNAi multiparametric profiles identifies triggers of intracellular mycobacterial killing. Cell Host Microbe 13 (2013), 129–142.
60. Rybniker, J., et al. Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. Nat. Commun., 6, 2015, 7659.
61. Jayaswal, S., et al. Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog., 6, 2010, e1000839.
62. Kumar, D., et al. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 140 (2010), 731–743.
63. Silva-Miranda, M., et al. High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59 (2015), 693–697.
64. Bielecka, M.K., et al. A bioengineered three-dimensional cell culture platform integrated with microfluidics to address antimicrobial resistance in tuberculosis. MBio 8 (2017), e02073–16.
65. Kramnik, I., Beamer, G., Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies. Semin. Immunopathol. 38 (2016), 221–237.
66. Nathan, C., Cooperative development of antimicrobials: looking back to look ahead. Nat. Rev. Microbiol. 13 (2015), 651–657.